JP2020514283A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020514283A5 JP2020514283A5 JP2019535260A JP2019535260A JP2020514283A5 JP 2020514283 A5 JP2020514283 A5 JP 2020514283A5 JP 2019535260 A JP2019535260 A JP 2019535260A JP 2019535260 A JP2019535260 A JP 2019535260A JP 2020514283 A5 JP2020514283 A5 JP 2020514283A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- fibrosis
- compound according
- pharmaceutical composition
- celiac
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 208000015943 Coeliac disease Diseases 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 241000251468 Actinopterygii Species 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 241000222122 Candida albicans Species 0.000 claims 1
- 206010007134 Candida infections Diseases 0.000 claims 1
- 208000002177 Cataract Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 108010068370 Glutens Proteins 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010023421 Kidney fibrosis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 201000003984 candidiasis Diseases 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 235000021312 gluten Nutrition 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000009759 skin aging Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16207029.6A EP3342779A1 (en) | 2016-12-27 | 2016-12-27 | Inhibitors of transglutaminases |
| EP16207029.6 | 2016-12-27 | ||
| US201762499528P | 2017-01-30 | 2017-01-30 | |
| US62/499,528 | 2017-01-30 | ||
| PCT/EP2018/050085 WO2018122419A1 (en) | 2016-12-27 | 2018-01-02 | Inhibitors of transglutaminases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020514283A JP2020514283A (ja) | 2020-05-21 |
| JP2020514283A5 true JP2020514283A5 (https=) | 2021-01-21 |
| JP7648339B2 JP7648339B2 (ja) | 2025-03-18 |
Family
ID=57777445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019535260A Active JP7648339B2 (ja) | 2016-12-27 | 2018-01-02 | トランスグルタミナーゼ阻害剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11072634B2 (https=) |
| EP (2) | EP3342779A1 (https=) |
| JP (1) | JP7648339B2 (https=) |
| CN (1) | CN110088120A (https=) |
| AU (1) | AU2018205019C1 (https=) |
| CA (1) | CA3044487A1 (https=) |
| ES (1) | ES2949273T3 (https=) |
| WO (1) | WO2018122419A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4067368A1 (en) | 2016-06-01 | 2022-10-05 | Athira Pharma, Inc. | Compounds |
| WO2019201432A1 (en) * | 2018-04-17 | 2019-10-24 | Zedira Gmbh | Inhibitors of blood coagulation factor xiii |
| TWI825144B (zh) * | 2018-08-10 | 2023-12-11 | 美商思達利醫藥公司 | 第二型轉麩醯胺酸酶(tg2)抑制劑 |
| CA3189027A1 (en) | 2020-07-11 | 2022-01-20 | Pfizer Inc. | Antiviral heteroaryl ketone derivatives |
| WO2022022612A1 (en) * | 2020-07-29 | 2022-02-03 | Jacobio Pharmaceuticals Co., Ltd. | Novel glutamine analogs |
| US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
| WO2023110138A1 (en) * | 2021-12-17 | 2023-06-22 | Zedira Gmbh | Inhibitors of transglutaminases |
| AU2022301517A1 (en) * | 2021-06-30 | 2023-12-14 | Zedira Gmbh | Inhibitors of transglutaminases |
| PL4192813T3 (pl) * | 2021-06-30 | 2024-12-23 | Zedira Gmbh | Inhibitory transglutaminaz |
| KR20240028466A (ko) * | 2021-06-30 | 2024-03-05 | 제디라 게엠베하 | 트랜스글루타미나아제 억제제 |
| WO2025153465A1 (en) | 2024-01-15 | 2025-07-24 | UCB Biopharma SRL | Method for the treatment of fibrotic-related disorder associated to ibd |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10054687A1 (de) * | 2000-11-03 | 2002-05-16 | N Zyme Biotec Gmbh | Inhibitoren von Transglutaminasen |
| WO2006018164A2 (de) | 2004-08-11 | 2006-02-23 | N-Zyme Biotec Gmbh | Fluoreszenzbasierende kinetische bestimmung der aktivität von transglutaminasen |
| DE102006052755A1 (de) * | 2006-11-08 | 2008-05-15 | N-Zyme Biotec Gmbh | Michaelsysteme als Transglutaminaseinhibitoren |
| US8614233B2 (en) * | 2007-05-29 | 2013-12-24 | Universite De Montreal | Cinnamoyl inhibitors of transglutaminase |
| AU2012327243A1 (en) * | 2012-08-17 | 2014-03-06 | Celexion, Llc | Biological synthesis of difunctional hexanes and pentanes from carbohydrate feedstocks |
-
2016
- 2016-12-27 EP EP16207029.6A patent/EP3342779A1/en not_active Ceased
-
2018
- 2018-01-02 JP JP2019535260A patent/JP7648339B2/ja active Active
- 2018-01-02 EP EP18700023.7A patent/EP3405477B1/en active Active
- 2018-01-02 WO PCT/EP2018/050085 patent/WO2018122419A1/en not_active Ceased
- 2018-01-02 CA CA3044487A patent/CA3044487A1/en active Pending
- 2018-01-02 CN CN201880005223.3A patent/CN110088120A/zh active Pending
- 2018-01-02 AU AU2018205019A patent/AU2018205019C1/en active Active
- 2018-01-02 US US16/473,265 patent/US11072634B2/en active Active
- 2018-01-02 ES ES18700023T patent/ES2949273T3/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020514283A5 (https=) | ||
| MA51739A (fr) | Compositions pharmaceutiques pour le traitement de la fibrose kystique | |
| CY1124084T1 (el) | Αμιδο-υποκατεστημενα παραγωγα πυριδινυλοτριαζολης και χρησεις αυτων | |
| EP4218754A3 (en) | Methods of treatment for cystic fibrosis | |
| WO2017087608A8 (en) | Modulators of ror-gamma | |
| MA47688A (fr) | Compositions utiles dans le traitement de l'amyotrophie spinale | |
| BR112014017780A8 (pt) | Compostos de sulfona tricíclicos e métodos para fazer e usar os mesmos | |
| WO2017194782A3 (en) | Therapeutic targeting of non-cellular structures | |
| JP2014221779A5 (https=) | ||
| WO2017062468A8 (en) | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof | |
| EP3412292B8 (en) | Use of methoxatin, derivative and/or salt thereof in sjogren's syndrome and pharmaceutical composition | |
| WO2017105565A3 (en) | Compositions for therapeutics, targeted pet imaging and methods of their use | |
| EP3672587A4 (en) | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES | |
| MX380531B (es) | Agonistas del receptor activado por proliferador de peroxisoma (ppar), compuestos, composiciones farmacéuticas y métodos para usar los mismos. | |
| WO2016057658A8 (en) | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof | |
| MA52644A (fr) | Compositions pharmaceutiques comprenant de l'acide dgla et leur utilisation | |
| JP2016540015A5 (https=) | ||
| MX390077B (es) | Inhibidor de bromodominio. | |
| WO2018234871A3 (en) | COMPOSITIONS FOR DRUG DELIVERY AND METHODS OF USE | |
| EP3846843A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEART DISEASES | |
| EP3911361A4 (en) | SALT NANOPARTICLES, AND COMPOSITIONS AND METHODS OF USE THEREOF | |
| JP2013053088A5 (https=) | ||
| EP3817744A4 (en) | IVOSIDENIB FORMS AND PHARMACEUTICAL COMPOSITIONS | |
| PH12021550090A1 (en) | Composition comprising glycyrrhizin and cosmetic and pharmaceutical uses thereof | |
| EP3930700A4 (en) | BIS-BIGUANIDE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES FOR CANCER MANAGEMENT |